Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:17 PM ET 8-K
Financial Results Atrium Therapeutics, Inc. RNA

Atrium Therapeutics Financial Results

Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.

Term
Q3 2026

“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”

Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics

“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”

Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
4:17 PM ET 8-K
M&A Deal Ardent Health, Inc. ARDT

Ardent Health Signs $47M M&A Deal with Boone Health

Ardent Health (NYSE: ARDT) has entered into a definitive agreement to acquire Boone Health, a Missouri-based not-for-profit health system, for $47 million in cash. The deal includes a 392-bed hospital and 19 sites of care, with Ardent committing an additional $200 million in capital investments over the next 10 years. The transaction is expected to close in Q1 2027 and be 6-8% accretive to Ardent's Adjusted EBITDA by the third year.

Value
$47M
Counterparty
Boone Health
4:17 PM ET 10-Q
Financial Results Blackstone Private Real Estate Credit & Income Fund

Blackstone Private Real Estate Credit & Income Fund Q3 2026 Results: Net Income $24.6M, Up 91.7% YoY

Blackstone Private Real Estate Credit and Income Fund reported total assets of $2.57 billion as of September 30, 2026, a significant increase from $1.58 billion at year-end 2025. Net investment income for the nine months ended September 30, 2026, was $65.3 million, driven by interest income from its growing portfolio of senior loans and debt securities.

Key figure
Net income $24.6M · +91.7% YoY
4:16 PM ET 10-Q
Financial Results ADARx Pharmaceuticals, Inc. ADRX

ADARx Pharmaceuticals Q3 2026 Results: Net Loss of $28.1M, Loss Widens

ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.

Key figure
Net loss $28.1M
4:16 PM ET 10-Q
Financial Results Once Upon a Farm, PBC OFRM

Once Upon a Farm, PBC Q3 2026 Results: Net Loss of $3.81M, Loss Narrows

Once Upon a Farm, PBC reported net sales of $247.2 million for the nine months ended September 30, 2026, a significant increase from $176.7 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $24.6 million for the first nine months of 2026, though this was an improvement over the $39.8 million net loss reported for the same period in 2025.

Key figure
Net loss $3.81M
4:16 PM ET 10-Q
Financial Results Skyx Platforms Corp. SKYX

Skyx Platforms Q3 2026 Results: Net Loss of $6.44M, Loss Narrows

As of September 30, 2026, SKYX Platforms Corp. reported a significant increase in cash and cash equivalents to $19.4 million, up from $8.1 million at the end of 2025. Total assets grew to $63.3 million, while total liabilities decreased to $49.3 million, primarily driven by reductions in operating lease liabilities and convertible notes.

Key figure
Net loss $6.44M
4:16 PM ET 10-Q
Financial Results Vylor Inc. VYLR

Vylor Q3 2026 Results: Net Loss of $475M, Loss Widens

Vylor Inc. (formerly the Seed Business of Corteva) became an independent public company on October 1, 2026, following a tax-free spin-off. For the nine months ended September 30, 2026, the company reported net sales of $13,742 million and net income attributable to the company of $1,311 million, compared to $13,491 million and $1,646 million respectively in the prior year period.

Key figure
Net loss $475M
4:16 PM ET 8-K
Financial Results AmpliTech Group, Inc. AMPG

AmpliTech Group Financial Results

AmpliTech Group reported Q3 2026 revenue of $6.58 million, an 8.0% increase year-over-year, driven by strong growth in its Spectrum Semiconductor Materials distribution business. The company narrowed its net loss sequentially to $1.89 million and reported a significant backlog surpassing $52 million as of October 2026.

Term
Q3 2026
4:16 PM ET 8-K
Financial Results Volitionrx Ltd VNRX

Volitionrx Financial Results

VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.

Term
Q3 2026

“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”

Cameron Reynolds, President and Group Chief Executive Officer
4:16 PM ET 8-K
Financial Results Tenon Medical, Inc. TNON

Tenon Medical Financial Results

Tenon Medical reported third quarter 2026 revenue of $1.4 million, a 22% increase year-over-year, driven by the commercial launch of its 3D-printed lateral screw for the SImmetry+ system. The company strengthened its balance sheet by raising $15.6 million in gross proceeds, repaying $5.12 million in convertible notes, and ending the quarter with $8.3 million in cash.

4:16 PM ET 10-Q
Financial Results Vyome Holdings, Inc HIND

Vyome Holdings Q3 2026 Results: Net Loss of $885K, Loss Narrows

Vyome Holdings reported a net loss of $2.64 million for the nine months ended September 30, 2026, a significant improvement from the $9.20 million loss in the prior year period which was impacted by high transactional fees. The company strengthened its cash position to $6.96 million through ATM financing activities, while research and development expenses increased substantially to $1.58 million.

Key figure
Net loss $885K
4:16 PM ET 8-K
Financial Results GCT Semiconductor Holding, Inc. GCTS

GCT Semiconductor Holding Financial Results

GCT Semiconductor reported Q3 2026 financial results with revenue increasing 148.6% year-over-year to $1.1 million. The company highlighted that year-to-date 5G chipset shipments exceeded 11,300 units and expanded its addressable market into terrestrial-based location services.

Term
Q3 2026

“We continued to make progress across our 5G customer programs in the third quarter, advancing integration and certification work with existing customers while expanding the range of applications our 5G chipsets can serve.”

John Schlaefer, Chief Executive Officer of GCT
4:16 PM ET 8-K
Business Update Bally's Chicago, Inc.

Bally's Chicago Business Update

Bally’s Chicago Operating Company entered into a Master Managed Technology Services Agreement and an Exclusive Neutral Host Lease Agreement with Tillman Digital Cities LLC. The agreements provide technology infrastructure and wireless connectivity for the company's permanent casino resort development in downtown Chicago. The 10-year agreements involve estimated annual payments of $8.4 million for infrastructure and approximately $1.1 million per year for monthly services.

Counterparty
Tillman Digital Cities LLC
Term
10 years
4:16 PM ET 10-Q
Financial Results Assembly Biosciences, Inc. ASMB

Assembly Biosciences Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.

Key figure
Net loss $20.3M
4:16 PM ET 8-K
Financial Results Rocket Pharmaceuticals, Inc. RCKT

Rocket Pharmaceuticals Financial Results

Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.

Term
Q3 2026

“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”

Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
4:16 PM ET 8-K
Financial Results QXO, Inc. QXO

QXO Financial Results

QXO, Inc. reported third quarter 2026 financial results, including net sales of $4.9 billion and an adjusted EBITDA of $557 million. The results reflect the integration of legacy Beacon, Kodiak, and TopBuild businesses, with management targeting $50 billion in annual revenue within the decade. Additionally, the Board of Directors authorized a new $500 million common stock repurchase program.

“Our organic daily revenue trends improved for the second consecutive quarter despite a soft construction market. Companywide pricing increased 2.2% year over year. We’re prioritizing higher-margin products; in Roofing and Waterproofing, complementary product sales grew 4.2%, and TRI-BUILT reached a record 10.6% of sales. Mechanical insulation distribution revenue grew 16%, supported by strong data center demand.”

Brad Jacobs, chairman and chief executive officer of QXO

“We’re on track to reach $4 billion in adjusted EBITDA by 2030 from the businesses we already own and $50 billion in annual revenue within the decade through organic growth and disciplined acquisitions.”

Brad Jacobs, chairman and chief executive officer of QXO
4:16 PM ET 10-Q
Financial Results ARC Group Acquisition I Corp. ARCL

ARC Group Acquisition I Q3 2026 Results: Turns Profitable, Net Income $720K

ARC Group Acquisition I Corp. reported a net income of $1,318,548 for the nine months ended September 30, 2026, primarily driven by $1,822,314 in interest income from its trust account. The company completed its initial public offering in May 2026, resulting in $122,572,314 held in trust and 12,075,000 Class A ordinary shares subject to possible redemption.

Key figure
Net income $720K
4:16 PM ET 8-K
M&A Deal First Advantage Corp FA

First Advantage M&A Deal with Silver Lake Group, L.L.C.

First Advantage Corporation announced the closing of a secondary offering of 15,000,000 shares of common stock by investment funds affiliated with Silver Lake Group. The company did not sell any shares and received no proceeds from the transaction, which served to facilitate the resale of shares by the selling stockholder. The offering closed on November 12, 2026, following the entry into an underwriting agreement with Barclays and J.P. Morgan.

Counterparty
Silver Lake Group, L.L.C.
4:16 PM ET 8-K
Financial Results NeoVolta Inc. NEOV

NeoVolta Financial Results

NeoVolta reported financial results for the quarter ended September 30, 2026, showing a sequential revenue rebound to $2.8 million driven by its residential third-party ownership (TPO) platform. The company also highlighted a $116 million Master Purchase Agreement for utility-scale products and a strategic 9 GWh battery cell supply collaboration with SK On.

Term
Q1 2027
4:16 PM ET 10-Q
Financial Results Equillium, Inc. EQ

Equillium Q3 2026 Results: Net Loss of $4.58M, Loss Widens

Equillium, Inc. reported a net loss of $4.6 million for the third quarter of 2026, with cash and cash equivalents increasing to $53.3 million as of September 30, 2026, following a private placement. Subsequent to the quarter-end, the company raised an additional $20.0 million in gross proceeds, which management believes will fund operations for at least the next 12 months.

Key figure
Net loss $4.58M
4:16 PM ET 8-K
Investor Presentation FS KKR Capital Corp FSK

FS KKR Capital Investor Presentation

FS KKR Capital Corp. announced that it will make investor presentations available on its website after the market close on November 12, 2026. The materials will be hosted on the company's investor relations page under the Events & Presentations section.

4:16 PM ET 8-K
Investor Presentation Weyerhaeuser Co WY

Weyerhaeuser Investor Presentation

Weyerhaeuser Company filed a formal investor presentation outlining its strategic goals through 2030, including an accelerated growth strategy to add $1.5 billion of incremental Adjusted EBITDA. The presentation highlights long-term targets for its timberlands, wood products, and natural climate solutions businesses, as well as its capital allocation framework and sustainability goals.

4:16 PM ET 10-Q
Financial Results XTI Aerospace, Inc. XTIA

XTI Aerospace Q3 2026 Results: Turns Profitable, Net Income $26M

XTI Aerospace reported total assets of $69.9 million as of September 30, 2026, a decrease from $81.2 million at year-end 2025, primarily driven by a reduction in cash and the disposal of its discontinued Inpixon Business. The company's balance sheet reflects significant liabilities including a $24.5 million warrant liability and the introduction of a $5.9 million asset-based revolving line of credit.

Key figure
Net income $26M
4:16 PM ET Form 4
Insider Selling Arxis, Inc. ARXS

Arxis Insider Kevin Scott Perhamus Sells $1.27M of Stock

Kevin Scott Perhamus sold 25,000 shares of Arxis, Inc. at $50.59 to $51.19 a share (average $50.92) in 2 transactions, worth $1.27M in total on Nov 9, 2026. Shares held after the trade: 3,548,133 (-0.4%).

Value
$1.27M
Shares
25,000
Average price
$50.92
Holding change
-0.4%
Trade date
Nov 9, 2026
4:16 PM ET Form 4
Insider Selling Paylocity Holding Corp PCTY

Paylocity Holding Insider Steven I. Sarowitz Sells $1.32M of Stock

Steven I. Sarowitz sold 7,300 shares of Paylocity Holding Corp at $180.14 to $181.16 a share (average $180.45) in 3 transactions, worth $1.32M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 4,341,095 (-0.0%).

Value
$1.32M
Shares
7,300
Average price
$180.45
Holding change
-0.0%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:16 PM ET Form 4
Insider Selling Teva Pharmaceutical Industries Ltd TEVA

Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock

Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).

Value
$1.93M
Shares
45,003
Average price
$42.86
Role
EVP, Europe Commercial
Holding change
-26.4%
Trade date
Nov 9, 2026 to Nov 11, 2026
4:16 PM ET 8-K
Financial Results Flowers Foods Inc FLO

Flowers Foods Financial Results

Flowers Foods reported third quarter 2026 net sales of $1.169 billion, a 4.7% decrease year-over-year as favorable pricing was offset by lower volumes. Net income fell 63.6% to $14.4 million due to higher logistics costs and marketing investments, leading the company to lower its full-year 2026 financial guidance.

Term
12 weeks

“Our third-quarter results reflect a continued challenging operating environment, driven by pressure on household budgets, evolving consumer behavior and heightened promotional activity, as well as areas where we need to move faster with focused execution.”

Ryals McMullian, chairman and CEO of Flowers Foods

“While it will take time for our initiatives to translate more fully into results, we believe they are putting Flowers on a stronger path forward. We expect the environment to remain challenging in the near term, but we remain confident in the long-term potential of the business.”

Ryals McMullian, chairman and CEO of Flowers Foods
4:16 PM ET 8-K
Business Update Immix Biopharma, Inc. IMMX

Immix Biopharma Business Update

Immix Biopharma reported its Q3 2026 operational progress, highlighting an 89% complete response rate in its NEXICART-2 clinical trial for NXC-201. The company strengthened its leadership team with new SVPs of Technical Operations and Regulatory Affairs as it prepares for a planned BLA submission in mid-2027.

4:16 PM ET 8-K
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.

Term
Q3 2026

“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”

J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
4:16 PM ET 8-K
Financial Results Azitra, Inc. AZTR

Azitra Financial Results

Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.

Term
Q3 2026

“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”

Francisco Salva, Chief Executive Officer

“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”

Francisco Salva, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.